Cytotoxicity mediation of cells evidencing surface expression of CD63
US7431923B2 · kind B2 · utility
6Cited by
15References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 29, 2005 |
| Grant date | Oct 7, 2008 |
| Priority date | — |
| Expiry date | Dec 29, 2025 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70596
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMABs of the instant invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.